Form: 6-K

Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

July 13, 2015


SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K
 

REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 under
the Securities Exchange Act of 1934
 
For the month of: July 2015
Commission File Number: 001-35776
 

 
ACASTI PHARMA INC.
(Name of Registrant)


545 Promende du Centropolis
Suite 100
Laval, Québec
Canada H7T 0A3
(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F  x            Form 40-F  ¨
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ¨
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ¨
 
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes  ¨             No  x
 
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): N/A
 

 
This Report on Form 6-K including the exhibits hereto shall be deemed to be incorporated by reference into Acasti Pharma Inc.’s registration statement on Form F-10 (File No. 333-191907) and to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.
 
 
 

 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
   
ACASTI PHARMA INC.
 
 
 
Date: July 13, 2015
By:
/s/ Pierre Lemieux
   
Name: Pierre Lemieux
Title: Chief Operating Officer

 

 

 

 

 

 
 
 

 
EXHIBIT INDEX
 
 
   
Exhibit
Description of Exhibit
   
99.1
Acasti MD&A for the Three-Month Periods Ended May 31, 2015 and 2014
   
99.2
Acasti Interim Financial Statements for the Three-Month Periods Ended May 31, 2015 and 2014
   
99.3
Acasti CEO Certification – Form 52-109 F2
   
99.4
Acasti CFO Certification – Form 52-109 F2